EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

SNRPC ‐ DHX9 ‐ RelA Complex Drives Cell‐Cycle Signaling and CDK4 /6 Inhibitor Sensitivity in Hepatocellular Carcinoma

Jiaojiao Xie, Yue Wu, Xiaohan Qian, Jingwen Huang, Tingting Jia, Saiyan Bian, Runzhou Ni, Xuying Zhao, Xiaoli Huang iD

Cancer Science · 11.11.2026

DOI: 10.1111/cas.70589 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, online erschienen am 11.11.2026. Verfasst von Jiaojiao Xie und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The Fourth Affiliated Hospital of Nanjing Medical University, Nanjing, China. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Jiangsu Commission of Health, Nanjing Municipal Health Commission, the Fourth Affiliated Hospital of Nanjing Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SNRPC is a core spliceosomal protein, but its oncogenic function and therapeutic relevance in hepatocellular carcinoma (HCC) remain incompletely defined. Here, we found that SNRPC was upregulated in HCC tissues and was associated with adverse clinicopathological features and poor survival. In the TCGA‐LIHC cohort, high SNRPC expression remained associated with poorer overall survival after multivariable adjustment. Gain‐ and loss‐of‐function studies showed that SNRPC promoted HCC cell proliferation and migration in vitro and tumor growth in vivo. Mechanistically, SNRPC interacted with DHX9 and RelA/p65 to form a functional complex that enhanced NF‐κB signaling and downstream CDK4/6‐E2F1 signaling. Mutational analysis showed that the ATP‐binding residue K417 of DHX9 contributed to RelA/p65 Ser536 phosphorylation, supporting a functional role for DHX9 in this signaling complex. Consistently, SNRPC or DHX9 depletion altered cell‐cycle distribution and reduced NF‐κB‐associated cell‐cycle signaling. Finally, the CDK4/6 inhibitor palbociclib markedly suppressed the enhanced growth of SNRPC‐ or DHX9‐overexpressing xenografts. These findings identify a non‐canonical oncogenic function of SNRPC in HCC and provide a mechanistic rationale for further evaluating CDK4/6 inhibition in tumors characterized by activation of the SNRPC/DHX9 signaling network.

Schlagwörter

Stichwörter der Autor:innen

DHX9RelASNRPChepatocellular carcinomapalbociclib

Autor:innen und Institutionen

  • Department of Gastroenterology, The Fourth Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Department of Gastroenterology, Affiliated Hospital of Nantong University, Nantong, China.
  • Department of Gastroenterology, Yixing People's Hospital, Wuxi, China.
  • Department of Oncology, Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China.
  • Department of Endocrinology and Metabolism, Affiliated Hospital of Nantong University, Nantong, China.

ORCID-Profile: Xiaoli Huang

Förderung

  • Jiangsu Commission of Health
  • Nanjing Municipal Health Commission
  • the Fourth Affiliated Hospital of Nanjing Medical University
  • Nantong Municipal Health Commission
  • Natural Science Foundation of Nantong City
  • Natural Science Foundation of Nantong Municipality

Zitieren

APA

Xie, J., Wu, Y., Qian, X., Huang, J., Jia, T., Bian, S., Ni, R., Zhao, X., & Huang, X. (2026). SNRPC ‐ DHX9 ‐ RelA Complex Drives Cell‐Cycle Signaling and CDK4 /6 Inhibitor Sensitivity in Hepatocellular Carcinoma. Cancer Science. https://doi.org/10.1111/cas.70589

Vancouver

Xie J, Wu Y, Qian X, Huang J, Jia T, Bian S, et al. SNRPC ‐ DHX9 ‐ RelA Complex Drives Cell‐Cycle Signaling and CDK4 /6 Inhibitor Sensitivity in Hepatocellular Carcinoma. Cancer Science. 2026. doi:10.1111/cas.70589

BibTeX
@article{Xie2026,
  author = {Xie, Jiaojiao and Wu, Yue and Qian, Xiaohan and Huang, Jingwen and Jia, Tingting and Bian, Saiyan and Ni, Runzhou and Zhao, Xuying and Huang, Xiaoli},
  title = {SNRPC ‐ DHX9 ‐ RelA Complex Drives Cell‐Cycle Signaling and CDK4 /6 Inhibitor Sensitivity in Hepatocellular Carcinoma},
  journal = {Cancer Science},
  year = {2026},
  doi = {10.1111/cas.70589}
}
Kostenlos starten →